NEW YORK (GenomeWeb) – Interpace Diagnostics said on Monday that it has entered into a purchase agreement with a single institutional investor to raise about $1.7 million in net proceeds in a direct stock offering.

Under the terms of the deal, the unnamed investor will purchase 2 million shares of Interpace's common stock at $.53 per share and 1.6 million prefunded warrants to purchase common stock at $.52 per share. The offering is anticipated to close on or about Dec. 22. Maxim Group acted as the exclusive placement agent for the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.